SOBRsafe Inc. (NASDAQ: SOBR), a provider of next-generation alcohol detection technology, announced it has entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share. The transaction is expected to generate approximately $3.1 million in gross proceeds before fees and expenses, according to a press release.
In connection with the offering, the company will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is expected to close on or about July 16, 2026, with net proceeds designated for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent.
The capital raise comes as SOBRsafe continues to expand its market presence with its advanced transdermal alcohol detection technology. Unlike traditional breath, blood, or urine tests, SOBRsafe's touch-based technology detects alcohol in real time as it is emitted through the skin. The company's platform serves behavioral health, family law, and consumer markets, as well as licensing and integration opportunities.
For more details, the full press release is available at https://nnw.fm/jzJjF. Additional information about SOBRsafe can be found at www.sobrsafe.com.
The transaction highlights SOBRsafe's strategy to strengthen its financial position while advancing its technology. With the proceeds, the company aims to support ongoing operations and potential growth initiatives. As the alcohol detection market evolves, SOBRsafe's non-invasive approach positions it as a key player in providing dignified screening and monitoring solutions.
